Cardiovascular · Antisense oligonucleotide

Pelacarsen

Pelacarsen is an injectable antisense drug that lowers lipoprotein(a), a genetically determined cardiovascular risk factor. Its 8,323-patient Phase 3 Lp(a)HORIZON trial did not reduce major cardiovascular events.

Major setbackPhase 3 outcomes trial missed its primary endpoint despite a 78% Lp(a) reduction

Major setback: A pivotal trial missed its main goal, or the FDA declined to approve the drug. Development may continue, and any approvals elsewhere are noted on the profile. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperNovartis (partners: Ionis Pharmaceuticals (originator)) · Novartis pipeline
Drug typeAntisense oligonucleotide
TargetLPA gene (apolipoprotein(a)) mRNA
MechanismReduces production of apolipoprotein(a) in the liver by targeting its messenger RNA, lowering lipoprotein(a)
Other namesTQJ230, AKCEA-APO(a)-LRx, IONIS-APO(a)-LRx, ISIS 681257

Key points

  • Pelacarsen lowers lipoprotein(a) [Lp(a)] by blocking production of its key protein in the liver.
  • Lp(a) is strongly supported by human genetics as a cause of heart disease, which made it one of the most anticipated new cardiovascular targets.
  • In the 8,323-patient Lp(a)HORIZON trial, pelacarsen lowered Lp(a) by 78% but did not reduce major adverse cardiovascular events compared with placebo.
  • Following the result, Novartis terminated an open-label extension study and withdrew a planned Phase 3 study, according to ClinicalTrials.gov.
  • The outcome raises the evidence bar for other Lp(a)-lowering drugs, including olpasiran, whose own outcomes trial is still running.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Elevated lipoprotein(a) with cardiovascular disease
Lp(a)HORIZON missed its primary endpoint (company-reported September 4, 2026; full results presented November 7, 2026). A benchmark for 'a Phase 3 program' does not apply after a failed pivotal outcomes trial.
Phase 3 completed (primary endpoint not met)15
4 active · 7 completed · 3 stopped
Not shown (see note)

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What pelacarsen is

Pelacarsen is an antisense oligonucleotide, a short synthetic strand of nucleic acid designed to bind the messenger RNA that carries instructions for making apolipoprotein(a), the protein that defines lipoprotein(a), or Lp(a). Binding the RNA prevents the protein from being made, so the liver releases less Lp(a) into the blood. It was discovered by Ionis Pharmaceuticals and developed by Novartis under the code name TQJ230. It is given as an injection under the skin.

Why the target looked so promising

Lp(a) is a cholesterol-carrying particle whose blood level is largely set by genetics. That makes it one of the clearest examples of a drug target supported by human genetic evidence:

  • A 2009 genetic study in the New England Journal of Medicine found that variants in the LPA gene that raise Lp(a) levels were associated with substantially higher odds of coronary disease, with odds ratios of 1.70 and 1.92 for two independent variants.
  • A 2009 study in JAMA found that people with genetically elevated Lp(a) had a higher risk of heart attack, supporting a causal role.

Because diet and exercise barely affect Lp(a), and no approved drug specifically lowers it, a drug that cut Lp(a) and prevented heart attacks would fill a large gap. Drug targets with genetic support have historically been more likely to succeed. See What Is Genomics?

Clinical evidence

Phase 2: Lp(a) lowering

In a Phase 2 trial of 286 patients with elevated Lp(a) and established cardiovascular disease, published in 2020, pelacarsen reduced Lp(a) in a dose-dependent manner. Mean decreases ranged from 35% at the lowest dose to 80% at 20 mg weekly, compared with 6% with placebo. The most common adverse events were injection-site reactions.

Phase 3: Lp(a)HORIZON

Lp(a)HORIZON was designed to answer the question that matters: does lowering Lp(a) with pelacarsen reduce heart attacks, strokes, and cardiovascular deaths?

Feature Detail
Participants 8,323 adults with elevated Lp(a) and established cardiovascular disease
Design Randomized, double-blind, placebo-controlled
Primary endpoint Time to first major adverse cardiovascular event
Lp(a) reduction 78% (presented at AHA Scientific Sessions 2026)
Primary result Did not meet its primary endpoint

On September 4, 2026, Ionis and Novartis announced that the trial did not meet its primary endpoint, while noting that "substantially lower" Lp(a) levels were achieved and that pelacarsen had an acceptable safety profile (company-reported, Ionis Form 8-K).

Full results were presented on November 7, 2026 at the American Heart Association's Scientific Sessions and published in the New England Journal of Medicine. According to the AHA summary of the presentation:

  • Pelacarsen reduced Lp(a) by 78%, but there was no change in the time to a major adverse cardiovascular event.
  • There was also no change in cardiovascular outcomes among patients with Lp(a) of 90 mg/dL or higher, the group many expected to benefit most.
  • Serious adverse events occurred in 37.3% of the pelacarsen group and 41.1% of the placebo group. Anaphylaxis occurred in 19 patients receiving pelacarsen and none receiving placebo.
  • About 21% of patients on pelacarsen and more than 7% on placebo stopped the study medication because of adverse reactions.

The study's senior author was quoted as saying the result did not mean Lp(a) is irrelevant, and called for further research.

Other trials

A smaller randomized trial in patients who require regular Lp(a) apheresis, a blood-filtering procedure, found that pelacarsen sharply reduced the need for apheresis sessions, with a placebo-adjusted Lp(a) change of −72% at 52 weeks (Lp(a)FRONTIERS APHERESIS, European Heart Journal, 2026). That trial measured the need for apheresis, not cardiovascular events.

Scientific perspective

Lp(a)HORIZON is one of the most important negative results in recent cardiovascular medicine because it breaks a chain of reasoning that looked unusually strong:

  1. Genetic studies indicated that higher Lp(a) causes heart disease.
  2. Pelacarsen lowered Lp(a) substantially and reliably.
  3. Lowering Lp(a) was therefore expected to reduce heart disease.

Step 3 did not hold in this trial. This is the core risk of any drug developed against a surrogate marker, as explained in What Is a Primary Clinical Trial Endpoint?. Several explanations remain possible, and none has been established: the residual Lp(a) after treatment may still have been too high for some patients, the benefit may require longer exposure than the trial provided, or Lp(a)'s contribution to risk in patients already receiving modern therapy may be smaller than genetic studies implied. Interpreting the result will depend on the detailed analyses now being published.

Development perspective

  • Program status: ClinicalTrials.gov lists an open-label extension study as terminated and a planned Phase 3 study as withdrawn, both "following the outcome of the Lp(a)HORIZON study." Other pelacarsen studies remain listed as active; their future had not been confirmed in the sources we reviewed.
  • Regulatory status: pelacarsen has no FDA approval. Without a positive outcomes trial, the path to approval for cardiovascular risk reduction is unclear.
  • Read-across: the result directly affects other Lp(a)-lowering drugs in development, including olpasiran, which uses a different mechanism (small interfering RNA) and achieves deeper Lp(a) lowering. Whether that difference matters is exactly what the remaining outcomes trials will test.

Competitive context

Several Lp(a)-lowering drugs are in development using different technologies, including small interfering RNAs (olpasiran, lepodisiran, zerlasiran) and an oral small molecule (muvalaplin). To our knowledge, Lp(a)HORIZON was the first cardiovascular outcomes trial of a drug designed specifically to lower Lp(a) to report results. Its neutral result means that, for now, no Lp(a)-lowering therapy has demonstrated a reduction in cardiovascular events in a completed outcomes trial.

Development timeline

  1. Mar 7, 2017Phase 2 dose-ranging trial in patients with elevated Lp(a) and cardiovascular disease begins (286 participants). Registry
  2. Dec 12, 2019Lp(a)HORIZON Phase 3 cardiovascular outcomes trial begins. Registry
  3. Jan 1, 2020Phase 2 results published: dose-dependent Lp(a) reductions of 35% to 80%, versus 6% with placebo. Peer-reviewed
  4. Jul 16, 2026Lp(a)HORIZON reaches primary completion with 8,323 participants enrolled. Registry
  5. Sep 4, 2026Ionis and Novartis announce that Lp(a)HORIZON did not meet its primary endpoint of reducing cardiovascular events. Company-reported
  6. Oct 15, 2026Open-label extension study terminated by the sponsor following the Lp(a)HORIZON outcome. Registry
  7. Nov 7, 2026Full results presented at AHA Scientific Sessions 2026 and published in the New England Journal of Medicine: Lp(a) fell 78% with no reduction in major cardiovascular events. Scientific meeting

What could change the outlook

  • Detailed analyses of Lp(a)HORIZON, including whether any prespecified subgroup, follow-up duration, or absolute Lp(a) reduction showed a different pattern.
  • Whether Novartis continues any remaining pelacarsen studies, such as those listed as active on ClinicalTrials.gov, or discontinues the program.
  • Results from other Lp(a)-lowering outcomes trials, which will show whether the HORIZON result reflects the drug, the trial design, or the Lp(a) hypothesis itself.
  • Scientific explanations reconciling strong genetic evidence for Lp(a) with the neutral trial outcome.

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Pelacarsen. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedOct 27, 2026

    CONDENSED FINANCIAL REPORT

    Selected innovative medicines projects awaiting regulatory decisions Completed submissions Product Indication US EU Japan News update Cosentyx Polymyalgia rheumatica Q1 2026 Q1 2026 Q1 2026 – Positive CHMP opinion – Efficacy supplement for IV regimen submitted to FDA Hidradenitis suppurativa, pediatrics aged 12+...

    Company
    Novartis
  2. Quarterly reportCompany-reportedOct 27, 2026

    FINANCIAL REPORT Q3 2026

    TQJ230 (pelacarsen) In the Phase III HORIZON trial, pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events versus placebo in patients with elevated Lp(a) and established cardiovascular disease (CVD), despite reducing Lp(a) levels in this study population.

    Company
    Novartis
  3. Trial resultsCompany-reportedSep 4, 2026

    Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated

    Lp(a) and established cardiovascular disease (CVD) Ad hoc announcement pursuant to Art. 53 Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of...

    Company
    Novartis

All Pelacarsen disclosures in Pipeline News

Clinical trials

18 registered trials list Pelacarsen as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Elevated lipoprotein(a) with cardiovascular disease

TrialPhaseStatusEnrollmentPrimary completionResults posted
Lp(a)HORIZON · NCT04023552
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Phase 3Completed8,323Jul 16, 2026No
NCT07517263
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Phase 3Active, not recruiting5,700 (est.)Jan 9, 2030 (est.)No
NCT06875973
Pelacarsen Roll-over Extension Program
Phase 3Active, not recruiting599 (est.)Dec 8, 2030 (est.)No
NCT06267560
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
Phase 3Completed422Mar 25, 2026No
ADD-VANTAGE · NCT06813911
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Phase 3Active, not recruiting246Feb 3, 2028 (est.)No
NCT05305664
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Phase 3Completed51Jan 28, 2025Yes
OLE · NCT05900141
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Why stopped (registry): Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
Phase 3Terminated41Oct 15, 2026No
NCT07625306
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
Why stopped (registry): Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint
Phase 3Withdrawn0Jan 22, 2029 (est.)No
NCT05646381
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Phase 2Recruiting502 (est.)Mar 12, 2030 (est.)No
NCT03070782
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Phase 2Completed286Jul 26, 2018Yes
5 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT02414594
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)
Phase 1Completed60Feb 2016No
NCT03392051
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel
Phase 1Completed18Mar 18, 2018No
NCT03426033
Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin
Phase 1Completed18Feb 25, 2018No
NCT04993664
Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
Why stopped (registry): Administrative reason
N/AWithdrawn0Jun 30, 2022 (est.)No
NCT07000695
Managed Access Programs for TQJ230, Pelacarsen
N/ANO_LONGER_AVAILABLE——No

Clinical pharmacology and supporting studies

3 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT05337878
A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants
Phase 1Completed29Dec 18, 2019No
NCT05026996
Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants
Phase 1Completed17Oct 19, 2022No
NCT03506854
Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients
Phase 1Completed16Oct 11, 2018No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Ionis Pharmaceuticals. Form 8-K, Exhibit 99.1: Lp(a)HORIZON topline results (September 4, 2026).Company-reported
  2. American Heart Association Newsroom. Lp(a) HORIZON trial: Lp(a) fell by 78%, but cardiovascular outcomes unexpectedly neutral (AHA Scientific Sessions 2026).Scientific meeting
  3. Tsimikas S, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. New England Journal of Medicine. 2020;382(3):244–255.Peer-reviewed
  4. Clarke R, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New England Journal of Medicine. 2009;361(26):2518–2528.Peer-reviewed
  5. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339.Peer-reviewed
  6. Parhofer KG, et al. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. European Heart Journal. 2026;47(25):3284–3294.Peer-reviewed
  7. ClinicalTrials.gov. Lp(a)HORIZON (NCT04023552).Registry
  8. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.